[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Ramia JM, Sancho E, Lozano O, Santos JM, Garrido F: [Primary small bowel lymphoma]. Cir Esp; 2007 Jan;81(1):46-8
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary small bowel lymphoma].
  • [Transliterated title] Linfoma primario de intestino delgado.
  • We present four patients with non-Hodgkin's lymphoma of the small bowel.
  • Three patients had large B-cell lymphomas and the remaining patient had a T-cell lymphoma associated with celiac disease.
  • Different combinations of chemotherapy were administered.
  • Only the patient with T-cell lymphoma died due to disease progression.
  • Clinical aspects and the therapeutic strategy used in these tumors are discussed.
  • [MeSH-major] Ileal Neoplasms. Jejunal Neoplasms. Lymphoma, Large B-Cell, Diffuse. Lymphoma, T-Cell

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17263959.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


2. Carreras JK, Goldschmidt M, Lamb M, McLear RC, Drobatz KJ, Sørenmo KU: Feline epitheliotropic intestinal malignant lymphoma: 10 cases (1997-2000). J Vet Intern Med; 2003 May-Jun;17(3):326-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feline epitheliotropic intestinal malignant lymphoma: 10 cases (1997-2000).
  • The clinical, histopathologic, and immunohistochemical features of 10 cats with epitheliotropic intestinal malignant lymphoma (EIL) are described.
  • Intestinal biopsy samples were reviewed by 3 pathologists to confirm the diagnosis of EIL.
  • These samples (n = 10) were compared to the intestinal biopsies of normal cats (n = 11), cats with inflammatory bowel disease (IBD; n = 7), and cats with non-EIL (n = 9) for quantification and immunophenotyping of intraepithelial lymphocytes.
  • EIL biopsies had markedly more intraepithelial lymphocytes than normal intestine (NRL) and samples from cats with IBD.
  • Regardless of the histologic diagnosis, the intraepithelial lymphocytes in all cats were small- to intermediate-sized T cells.
  • Most cats fit the typical profile of cats with IBD or alimentary malignant lymphoma.
  • Nine of 10 cats with EIL were treated with prednisone with or without additional chemotherapy.
  • Four cats were refractory to chemotherapy and were euthanized within 3.5 months.
  • The remaining 5 cats had long-term survival times of 11 months or greater.
  • The median survival time was 11 months.
  • Additional studies are warranted to better characterize EIL and its relationship to IBD in cats and non-EIL and to identify optimal treatment strategies for this disease.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12774974.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


3. Tadmor T, Rainis T, Bejar J, Attias D, Lavy A: Primary duodenal mucosa-associated lymphoid tissue (MALT) lymphoma--a rare presentation of gastric outlet obstruction. Can J Gastroenterol; 2007 Jun;21(6):393-5
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary duodenal mucosa-associated lymphoid tissue (MALT) lymphoma--a rare presentation of gastric outlet obstruction.
  • Malignant lymphoma of mucosa-associated lymphoid tissue (MALT) can arise in a variety of anatomical sites.
  • The majority of these tumors arise in the stomach, with fewer than 30% arising in the small intestine.
  • Primary duodenal MALT lymphoma is a very rare neoplasm.
  • There are very few cases of duodenal MALT lymphoma reported in the literature.
  • The patient was successfully treated with a combination of chemotherapy and rituximab.
  • [MeSH-major] Duodenal Neoplasms / complications. Gastric Outlet Obstruction / etiology. Lymphoma, B-Cell, Marginal Zone / complications

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2000 Feb;95(2):536-9 [10685764.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1979-83 [15668468.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Aug;14(8):893-6 [12172414.001]
  • [Cites] Br J Haematol. 2003 Oct;123(2):271-7 [14531908.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1410-6 [6193858.001]
  • [Cites] Cancer. 1984 Sep 1;54(5):895-8 [6547634.001]
  • [Cites] Cancer. 1985 Mar 1;55(5):1060-73 [3881161.001]
  • [Cites] Histopathology. 1987 May;11(5):445-62 [3497084.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):309-15 [3334966.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] Gastroenterology. 1992 May;102(5):1628-38 [1568573.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1662-71 [8253342.001]
  • [Cites] J Clin Pathol. 1994 May;47(5):436-9 [8027397.001]
  • [Cites] Lancet. 1995 Jun 24;345(8965):1591-4 [7783535.001]
  • [Cites] Gastrointest Endosc. 1995 Mar;41(3):258-61 [7789690.001]
  • [Cites] Gastroenterology. 1996 Dec;111(6):1674-8 [8942749.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • (PMID = 17571175.001).
  • [ISSN] 0835-7900
  • [Journal-full-title] Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • [ISO-abbreviation] Can. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2658124
  •  go-up   go-down


Advertisement
4. Nakamura S, Matsumoto T, Iida M: [Malignant lymphoma of the small intestine]. Nihon Rinsho; 2008 Jul;66(7):1297-302
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant lymphoma of the small intestine].
  • The clinicopathologic features of malignant lymphoma of the small intestine were reviewed.
  • Genetically, characteristic chromosomal translocations have been identified in several B-cell lymphomas, such as t (11 ; 18)/API2-MALT1 in MALT lymphoma, t (14 ; 18)/IGH-BCL2 in follicular lymphoma, or t (3 ; 14)/BCL6-IGH in diffuse large B-cell lymphoma (DLBCL).
  • Histologically, DLBCL is most frequently observed, and T-cell lymphoma and follicular lymphoma are more frequent in small intestinal cases than in gastric cases.
  • Macroscopically, small intestinal lymphomas are classified as polypoid, ulcerative (including stricturing, non-stricturing and aneurysmal forms on radiography), multiple lymphomatous polyposis, diffuse, or other types.
  • A significant correlation is observed between these macroscopic/radiographic and histologic types.
  • The therapeutic strategy, such as surgery, chemotherapy, antibiotics or watch-and-wait, should be determined based on the disease extent, histologic type, and clinical stage.
  • [MeSH-major] Intestinal Neoplasms. Intestine, Small. Lymphoma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18616120.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 13
  •  go-up   go-down


5. Alzubi A, Zöllei I, Krenács L, Intzédy K, Hudák J: [Primary T-cell lymphoma of the small bowel]. Magy Seb; 2008 Apr;61(2):79-83
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary T-cell lymphoma of the small bowel].
  • [Transliterated title] Primer vékonybél T-sejtes lymphoma operált esete.
  • Primary malignancies in the small intestine are relatively rare.
  • The authors report a case of a primary T-cell lymphoma in the small bowel that caused diagnostic challenges.
  • Blood tests, endoscopic examinations, ultrasonography and CT scan could not reveal a definitive diagnosis.
  • While a small bowel follow through examination demonstrated an entero-enteral fistula, its exact position could not have been determined.
  • Consequently, an exploratory laparotomy was carried out, and a tumour was found involving the small bowel loops.
  • The involved portion of the small intestine (with the fistula) was resected, and a side-to-side small bowel anastomosis was performed.
  • Histological and immunohistochemical analyses revealed a primary T-cell lymphoma of the small bowel.
  • There was no evidence of metastatic disease at the time of surgery.
  • The patient received adjuvant chemotherapy, but three months later multiple lung metastases were detected.
  • Small bowel malignant tumours cause significant diagnostic difficulties.
  • Therefore, diagnosis and adequate treatment are usually delayed for some weeks.
  • Nevertheless, surgical exploration and resection of the tumour will be necessary for the correct diagnosis and treatment.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / surgery. Intestine, Small / pathology. Lung Neoplasms / secondary. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / surgery
  • [MeSH-minor] Aged. Anastomosis, Surgical. Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Humans. Intestinal Fistula / diagnosis. Intestinal Fistula / surgery. Laparotomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18426712.001).
  • [ISSN] 0025-0295
  • [Journal-full-title] Magyar sebészet
  • [ISO-abbreviation] Magy Seb
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


6. Tokuhira M, Watanabe R, Iizuka A, Sekiguchi Y, Nemoto T, Hanzawa K, Takamatsu I, Maruyama T, Tamaru J, Itoyama S, Suzuki H, Takeuchi T, Mori S: De novo CD5+ diffuse large B cell lymphoma with basophilia in the peripheral blood: successful treatment with autologous peripheral blood stem cell transplantation. Am J Hematol; 2007 Feb;82(2):162-7
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] De novo CD5+ diffuse large B cell lymphoma with basophilia in the peripheral blood: successful treatment with autologous peripheral blood stem cell transplantation.
  • Here, we report the case of a 33-year-old man with a bulky mass of the small intestine, multiple paraaortic lymphoadenopathy, pleural effusion, and ascites, who was diagnosed as a case of de novo CD5+ diffuse large B cell lymphoma (DLBCL).
  • High dose chemotherapy followed by autologous peripheral blood cell transplantation yielded complete remission, and the patient has remained disease free for 5 years.
  • To the best of our knowledge, this is the first report of a case of de novo CD5+ DLBCL showing marked elevation of the PB basophil count.
  • [MeSH-major] Antigens, CD5. Basophils. Intestinal Neoplasms / therapy. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Peripheral Blood Stem Cell Transplantation. Pleural Effusion, Malignant / therapy
  • [MeSH-minor] Adult. Ascites / blood. Ascites / pathology. Ascites / radiography. Ascites / therapy. Asian Continental Ancestry Group. Humans. Japan. Male. Remission Induction. Transplantation, Autologous. Tumor Burden

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 17019691.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD5
  •  go-up   go-down


7. Yamauchi K, Yasuda M: Comparison in treatments of nonleukemic granulocytic sarcoma: report of two cases and a review of 72 cases in the literature. Cancer; 2002 Mar 15;94(6):1739-46
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison in treatments of nonleukemic granulocytic sarcoma: report of two cases and a review of 72 cases in the literature.
  • BACKGROUND: The purpose of this study was to reveal the clinical characteristics of nonleukemic granulocytic sarcoma (GS) and an association between the therapeutic regimens and the nonleukemic period.
  • These patients were divided into 3 groups by therapeutic regimens; Group I included 12 patients who received only biopsy or surgical resection of the tumor, Group II was 20 patients who received local irradiation for the tumor, and Group III consisted of 42 patients who received systemic chemotherapy.
  • In Group III, the period in the patients who were treated with chemotherapy given to ANLL was compared with that in the patients who received chemotherapy used for malignant lymphoproliferative disorders (MLPDs).
  • RESULTS: Thirty-five patients (47%) initially were misdiagnosed, and the disease was most often malignant lymphoma.
  • Preferential sites of GS were the small intestine, mediastinum, epidural site, uterus, and ovary, which often are difficult for the detection and diagnosis in addition to the skin and lymph nodes known commonly.
  • The nonleukemic period after the diagnosis of GS was significantly longer in Group III than in the other groups (median, 12 months in Group III vs. 3 and 6 months in Groups I and II, respectively).
  • The aggressive chemotherapy given to ANLL led to a longer nonleukemic period than the chemotherapy used for MLPDs.
  • CONCLUSIONS: To reduce the risk of subsequent ANLL in patients with nonleukemic GS, it is important that accurate histologic diagnosis is established initially for GS and that all isolated cases of GS, even those that appear to be cured by resection or irradiation of the tumor, are treated with intensive chemotherapy similar to that used to treat ANLL during the nonleukemic period as soon as possible.
  • [MeSH-major] Leukemia, Myeloid, Acute / etiology. Sarcoma, Myeloid / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Humans. Lymphoma / diagnosis. Male. Middle Aged. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 11920536.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 59
  •  go-up   go-down


8. Han SL, Cheng J, Zhou HZ, Guo SC, Jia ZR, Wang PF: Surgically treated primary malignant tumor of small bowel: a clinical analysis. World J Gastroenterol; 2010 Mar 28;16(12):1527-32
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgically treated primary malignant tumor of small bowel: a clinical analysis.
  • AIM: To evaluate the clinical presentation, treatment and survival of patients with primary malignant tumor of small bowel (PMTSB).
  • RESULTS: The most common initial clinical features of the patients were intermittent abdominal discomfort or vague abdominal pain (67.4%), abdominal mass (31.2%), bowel obstruction (24.1%), hemotochezia (21.3%), jaundice (16.3%), fever (14.2%), coexistence of bowel perforation and peritonitis (5.7%), coexistence of gastrointestinal bleeding and shock (5.0%), and intraabdominal bleeding (1.4%).
  • Segmental bowel resection (n = 81) was the most common surgical procedure, followed by right hemi-colectomy (n = 15), pancreaticoduodenectomy (n = 10), and others (n = 19).
  • Twenty-seven adenocarcinoma patients and 13 malignant lymphoma patients received adjuvant chemotherapy with 5-fluorouracil and cyclophosphamide, adriamycin, vincristine and prednisone, respectively.
  • The median survival time of PMTSB patients was 20.3 mo.
  • Malignant lymphoma was demonstrated in 69.2% (9/13), 30.8% (4/13) and 0% (0/13) of the patients, respectively.
  • CONCLUSION: En bloc resection is the principal therapy for most PMTSB and chemotherapy is the important treatment modality for malignant lymphoma and other malignant tumors of small bowel which cannot be radically removed.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoid Tumor / surgery. Digestive System Surgical Procedures. Gastrointestinal Stromal Tumors / surgery. Intestinal Neoplasms / surgery. Intestine, Small / surgery. Lymphoma / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Time Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 2005;69(4):290-4 [16282708.001]
  • [Cites] Hepatogastroenterology. 2005 May-Jun;52(63):731-41 [15966194.001]
  • [Cites] Cancer Imaging. 2006;6:209-12 [17208678.001]
  • [Cites] World J Gastroenterol. 2007 Jan 21;13(3):432-7 [17230614.001]
  • [Cites] Ann Diagn Pathol. 2007 Feb;11(1):39-45 [17240306.001]
  • [Cites] Chirurgia (Bucur). 2006 Sep-Oct;101(5):477-81 [17278638.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Mar;19(2):143-9 [17355111.001]
  • [Cites] Arch Surg. 2007 Mar;142(3):229-35 [17372046.001]
  • [Cites] Hepatogastroenterology. 2007 Jan-Feb;54(73):129-34 [17419246.001]
  • [Cites] Ann Surg Oncol. 2007 Aug;14(8):2263-9 [17549572.001]
  • [Cites] Arch Surg. 2009 Jul;144(7):670-8 [19620548.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2693-706 [10594865.001]
  • [Cites] Am J Surg. 2000 Jan;179(1):37-41 [10737576.001]
  • [Cites] Arch Surg. 2000 Jun;135(6):635-41; discussion 641-2 [10843358.001]
  • [Cites] Hepatogastroenterology. 2001 May-Jun;48(39):727-32 [11462914.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Aug;57(2):169-83 [12153595.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S39-51 [12528772.001]
  • [Cites] J Gastrointest Surg. 2003 Nov;7(7):925-30 [14592670.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):469-81 [14713260.001]
  • [Cites] Int Surg. 2004 Jan-Mar;89(1):21-6 [15085993.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] Surg Clin North Am. 1986 Aug;66(4):779-85 [3738698.001]
  • [Cites] AJR Am J Roentgenol. 1989 May;152(5):995-8 [2705358.001]
  • [Cites] Zhonghua Liu Xing Bing Xue Za Zhi. 1994 Feb;15(1):46-50 [8082141.001]
  • [Cites] Ann Surg Oncol. 1995 Jan;2(1):26-31 [7834450.001]
  • [Cites] Ann Surg Oncol. 1994 May;1(3):183-8 [7842287.001]
  • [Cites] Ann Surg. 1997 Mar;225(3):262-7 [9060581.001]
  • [Cites] Oncology (Williston Park). 1997 Apr;11(4):529-36; discussion 545, 549-50 [9130275.001]
  • [Cites] Surg Endosc. 1997 Dec;11(12):1153-8 [9373284.001]
  • [Cites] J Comput Assist Tomogr. 1997 Nov-Dec;21(6):986-91 [9386295.001]
  • [Cites] Br J Cancer. 1999 Jul;80(9):1440-4 [10424748.001]
  • [Cites] World J Surg. 2006 Mar;30(3):391-8; discussion 399 [16479330.001]
  • (PMID = 20333796.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2846261
  •  go-up   go-down


9. Tamura H, Ogata K, Kondo A, Wakita T, Inami M, Mizuki T, Hyodo H, Shioi Y, Nakamura K, Mitsui K, Tanaka S, Sakamoto C, Dan K: [Double balloon endoscopy as a useful tool for the diagnosis and treatment of four cases of primary small intestinal lymphoma]. Rinsho Ketsueki; 2007 Jun;48(6):510-3
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Double balloon endoscopy as a useful tool for the diagnosis and treatment of four cases of primary small intestinal lymphoma].
  • Primary small intestinal lymphoma (PSIL) is a relatively rare form of non-Hodgkin lymphoma, often complicated by bleeding, obstruction, or perforation of the intestine during the clinical course.
  • The initial diagnosis and management of these complications are often difficult in PSIL, because the small intestine is usually inaccessible in routine endoscopy.
  • Recently, total enteroscopy with a double-balloon method, called double balloon endoscopy (DBE), has been developed for the diagnosis and treatment of small intestinal disorders.
  • In these cases, DBE was useful in the diagnosis, decision to perform surgery after assessment of bleeding lesion, and treatment of the intestinal stenosis using enteroscopic balloon dilatation.
  • Combination chemotherapy consisting of anthracycline, cyclophosphamide, vincristine, and prednisolone with rituximab was administered in 3 cases, and all achieved complete remission.
  • More PSIL cases must be analyzed to establish the optimal management of patients with this form of lymphoma.
  • [MeSH-major] Catheterization / methods. Endoscopes, Gastrointestinal. Endoscopy, Gastrointestinal / methods. Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / therapy. Intestine, Small. Lymphoma / diagnosis. Lymphoma / therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Fatal Outcome. Female. Humans. Male. Middle Aged. Prednisolone / administration & dosage. Rituximab. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633101.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


10. Chen CQ, Yin L, Peng CH, Zhao R, Chen GM, Zhou HJ, Li HW: [Primary non-Hodgkin lymphoma of small bowel: a clinical analysis of 34 cases]. Zhonghua Wei Chang Wai Ke Za Zhi; 2007 May;10(3):249-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary non-Hodgkin lymphoma of small bowel: a clinical analysis of 34 cases].
  • OBJECTIVE: To study the clinical characteristics,treatment and prognosis of primary non-Hodgkin's lymphoma of small bowel.
  • METHODS: The records of 34 patients with a confirmed diagnosis of primary non-Hodgkin's lymphoma of small bowel, registered between Jan.
  • RESULTS: Twenty-seven patients had B-cell lymphoma and 7 had T-cell lymphoma of the small bowel.
  • The major symptoms included abdominal pain and intestinal obstruction.
  • According to Ann Arbor staging classification, 22 patients belonged to stage I~II, including 20 cases of B-cell lymphoma and 2 cases of T-cell lymphoma, and 12 patients belonged to stage III~IV, including 7 cases of B-cell lymphoma and 5 cases of T-cell lymphoma.
  • Compared with T-cell lymphoma patients, B-cell lymphoma patients had lower lymphoma stages (P<0.05).
  • Fourteen patients were treated with six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) chemotherapy, and 8 patients were treated with Rituximab at the same time.
  • T-cell lymphoma patients were more often treated with emergent operation than B-cell lymphoma patients would (P<0.05).
  • It happened more frequently that B-cell lymphoma patients reached complete remission and their accumulative survival rate was longer than T-cell lymphoma patients did (P<0.05).
  • CONCLUSION: Patients with stages I and II B-cell lymphoma of small bowel respond well to surgery and chemotherapy, and the treatment and prognosis of patients with T-cell lymphoma of small bowel are unsatisfactory.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestine, Small / pathology. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17520384.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


11. Qureshi I, Awad ZT: Predictors of failure of the laparoscopic approach for the management of small bowel obstruction. Am Surg; 2010 Sep;76(9):947-50
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of failure of the laparoscopic approach for the management of small bowel obstruction.
  • Small bowel obstruction (SBO) is a common cause of hospital admission.
  • Twenty-three consecutive patients underwent diagnostic laparoscopy with curative intent for treatment of SBO by a single surgeon over a 3-year period.
  • The causes of obstruction included adhesive band in 16 patients; and small bowel lymphoma, metastatic esophageal cancer, small bowel gangrene, Meckel diverticulum, gallstones ileus, and incarcerated incisional hernia in two.
  • Using the Fisher two-sided test, no significant predictor for conversion was identified using gender, American Society of Anesthesiologists class, previous bowel obstruction, history of adhesiolysis, abdominal distention, pelvic surgeries, chemotherapy, radiation, malignancy, chronic obstructive pulmonary disease, asthma, coronary artery disease, hypertension, or hypercholesterolenemia.
  • The Wilcoxon two-sided test did not show significance for age, weight, number of previous abdominal surgeries, or small bowel diameter.
  • [MeSH-major] Intestinal Obstruction / surgery. Laparoscopy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Comorbidity. Female. Humans. Laparotomy. Length of Stay. Male. Middle Aged. Retrospective Studies. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20836340.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Koh PK, Horsman JM, Radstone CR, Hancock H, Goepel JR, Hancock BW: Localised extranodal non-Hodgkin's lymphoma of the gastrointestinal tract: Sheffield Lymphoma Group experience (1989-1998). Int J Oncol; 2001 Apr;18(4):743-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localised extranodal non-Hodgkin's lymphoma of the gastrointestinal tract: Sheffield Lymphoma Group experience (1989-1998).
  • Extranodal non-Hodgkin's lymphoma (NHL) of the gastrointestinal tract accounts for about one third of all extranodal NHL.
  • We retrospectively reviewed the clinical and histopathologic records of 71 patients with stage IE and IIE primary gastrointestinal NHL referred to the Sheffield Lymphoma Group (SLG) from 1989 to 1998.
  • The most common primary site was the stomach (45 patients, 63% of all cases), followed by the small intestine (16, 23%) and large intestine (9, 13%).
  • Mucosa-associated lymphoid tissue (MALT) lymphomas were the largest histologic subtype seen (57%), with 87% of these arising from the stomach; next most frequent was the diffuse large B-cell subtype (21% of all cases) most frequently arising from the intestine (60%).
  • For treatment of gastric MALT lymphoma, a combined approach (surgery followed by chemotherapy, antihelicobacter therapy followed by chemotherapy) was favoured (22 cases).
  • Knowledge of the Revised European American Lymphoma classification and the Helicobacter pylori/MALT association has influenced treatment approaches over the 10-year study period.
  • For small intestinal lymphoma, surgery (with or without chemotherapy) gave 5- and 10-year survivals of 60%.
  • Overall survival of patients with primary gastrointestinal lymphoma managed by the SLG is similar to that reported from other large series.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Great Britain. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11251169.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


13. Shukla K, Patel T, Shukla J, Palanki S: Primary gastrointestinal lymphoma--a clinicopathologic study. Indian J Pathol Microbiol; 2007 Apr;50(2):296-9
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastrointestinal lymphoma--a clinicopathologic study.
  • Gastrointestinal tract is the most common site for the development ofextra nodal lymphoma.
  • This study was done to analyze clinical and pathological features as well as the treatment outcome of this disease.
  • We carried out analysis of25 cases of primary gastrointestinal (GI) lymphomas during period from March 2001 to February 2003 at Gujarat Cancer & Research Institute.
  • Out of 25 cases of primary GI lymphoma, nine cases of gastric lymphoma, nine cases of small intestinal lymphoma and seven cases of large intestinal lymphoma were identified.
  • Diffuse large B-cell type and Burkitt's lymphoma were the most common histologic variants, accounting for equal proportions (36% each).
  • All the patients were treated with either surgery alone or in combination of surgery, chemotherapy and radiotherapy depending on the site, stage and histology.
  • 18 cases of GI lymphoma were evaluable, and out of these, 66.6% (11 cases) attained complete remission with a median follow up time of 12 months.
  • In conclusion, although there are considerable therapeutic controversies, surgery with adjuvant chemotherapy and radiotherapy yield good survival.
  • Clinical and histopathologic characteristics and prognosis of our cases with primary gastrointestinal lymphoma were usually similar to the cases in western countries with some differences in the incidence and histologic subtypes.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Helicobacter Infections / diagnosis. Helicobacter pylori / isolation & purification. Humans. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / therapy. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883049.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


14. Brueck M, Barton M, Rauber K, Zikova A, Kramer W: [Ileus of the small intestine in intestinal marginal-zone B-cell lymphoma of mucoid-associated lymphoid tissue (MALT)]. Dtsch Med Wochenschr; 2001 Dec 7;126(49):1391-5
MedlinePlus Health Information. consumer health - Small Intestine Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ileus of the small intestine in intestinal marginal-zone B-cell lymphoma of mucoid-associated lymphoid tissue (MALT)].
  • [Transliterated title] Dünndarmileus bei intestinalem Marginalzonen-B-Zell-Lymphom des MALT.
  • INVESTIGATIONS: Physical examination revealed signs of an acute abdomen with high-pitched bowel sounds and diffuse abdominal guarding.
  • The X-ray showed ileus of the small intestine which required emergency laparotomy.
  • It was removed by partial resection of the small intestine.
  • DIAGNOSIS: Ileus of the small intestine with a low-malignant marginal zone B-cell (non-Hodgkin) lymphoma of MALT type (mucoid-associated lymphoid tissue).
  • TREATMENT AND COURSE: Postoperative staging indicated no further manifestation of the lymphoma.
  • As no radical operation in resecting the tumour had been performed, combined radio- and chemotherapy was undertaken.
  • CONCLUSION: Marginal B-cell lymphomas of the small intestine are only rarely seen in central Europe.
  • Despite its usually slow growth this non-Hodgkin lymphoma of low malignancy can produce an acute mechanical ileus without prodromal symptoms.
  • A multimodal therapeutic approach is often employed, but there are no established treatment strategies.
  • [MeSH-major] Ileal Diseases / etiology. Intestinal Neoplasms / diagnosis. Intestinal Obstruction / etiology. Lymphoma, B-Cell, Marginal Zone / diagnosis

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11740631.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Cadoo KA, Lowery MA, Cumiskey J, McCaffrey J, Carney DN: Long term follow-up of primary B and T cell non-Hodgkin's lymphoma (NHL) of the gastrointestinal (GI) tract. J Clin Oncol; 2009 May 20;27(15_suppl):e19516

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long term follow-up of primary B and T cell non-Hodgkin's lymphoma (NHL) of the gastrointestinal (GI) tract.
  • : e19516 Background: Anthracycline based chemotherapy is the treatment of choice for aggressive primary lymphomas of the GI tract, with surgery reserved for management of complications.
  • We report long term follow up of 71 cases of primary GI NHL treated with chemotherapy and/or surgery.
  • Median age at diagnosis was 60 (15-83).
  • The 8 patients with MALT were treated with single agent chemotherapy; 7 (88%) are alive at median follow up of 8.5 years (2-16).
  • Of the aggressive lymphomas (63), all patients with T cell lymphoma had small bowel as primary site and histological evidence of celiac associated enteropathy, even in the absence of known celiac disease.
  • Primary sites of DLBCL were stomach 35 (67%), small bowel 11 (21%) & colon 6 (12%).
  • 39 (62%) patients underwent surgery at diagnosis due to acute presentation with perforation, bleeding or obstruction, or to obtain histology.
  • Following confirmed diagnosis, 61 patients received anthracycline based chemotherapy.
  • 2 patients with T cell lymphoma presented with perforation, were treated with surgery only and died of rapid disease progression.
  • Only 2 (18%) of the T cell lymphomas are alive & disease free.
  • 5 deaths in the DLBCL group were not related to cancer or treatment.
  • All deaths in the T cell group were due to progressive disease.
  • There was no difference in survival between patients treated with chemotherapy only and those who also underwent surgery.
  • CONCLUSIONS: Patients with aggressive primary B cell GI NHL have almost 70 % survival following anthracycline based chemotherapy.
  • However, in contrast, coeliac enteropathy associated T-cell lymphomas present with rapidly progressive disease & have a survival of < 20% with chemotherapy and/or surgery.
  • A novel therapeutic approach is required to improve outcome in this group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960953.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Rygoł B, Mykała-Cieśla J, Machalski M: [Malignant neoplasms of the small intestines]. Wiad Lek; 2004;57(1-2):33-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant neoplasms of the small intestines].
  • The paper contains a retrospective study of 12 cases of malignant small bowel tumors observed and treated in the Department of Oncological Chemotherapy of Medical University of Silesia.
  • The authors presented the most common symptoms, typical diagnostic procedures and the difficulties in the diagnostics of small bowel neoplasms.
  • [MeSH-major] Intestinal Neoplasms. Intestine, Small
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adult. Aged. Carcinoid Tumor / diagnosis. Diagnosis, Differential. Female. Humans. Lymphoma / diagnosis. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15181747.001).
  • [ISSN] 0043-5147
  • [Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)
  • [ISO-abbreviation] Wiad. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


17. Chen CQ, Yin L, Peng CH, Ye M, Zhao R, Chen GM, Zhou HJ, Li HW, Fan YZ: [Primary diffuse large B-cell non-Hodgkin's lymphoma of the small intestine: clinicopathologic features, management, and prognosis in 24 patients]. Zhonghua Zhong Liu Za Zhi; 2007 Sep;29(9):693-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary diffuse large B-cell non-Hodgkin's lymphoma of the small intestine: clinicopathologic features, management, and prognosis in 24 patients].
  • OBJECTIVE: To investigate the clinicopathological features of primary diffuse large B-cell lymphomas (DLBCLs) of the small intestine, CD10 expression, and their relationship to prognosis.
  • METHODS: Twenty-four cases of small intestinal DLBCLs were studied clinically and pathologically.
  • All cases were staged according to the Ann Arbor classification of lymphoma.
  • Twenty cases (83.3%) received surgical resection, sixteen cases (66.7%) received chemotherapy, and no patient received radiotherapy.
  • Although there was no statistically significant difference(P = 0.28) in therapy result between the CD10+ and CDO1--groups, patients with CD10+ lymphoma more frequently presented with stages I compared with those with CD10 - lymphoma (P = 0.013).
  • CONCLUSION: The primary small intestnal diffuse large B cell lymphoma patients at stage I and II respond better to therapy including surgical resection and chemotherapy than those at stage III and IV.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms. Intestine, Small / surgery. Lymphoma, Large B-Cell, Diffuse. Neprilysin / metabolism
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Remission Induction. Survival Rate. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18246801.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 3.4.24.11 / Neprilysin; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


18. Sakakibara T, Kurasawa T, Narumi K, Kamano T, Tsurumaru M: T-cell malignant lymphoma of the ileum causing ileac fistulas: report of a case. Surg Today; 2002;32(6):536-40
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell malignant lymphoma of the ileum causing ileac fistulas: report of a case.
  • We herein present a rare case of three fistulas caused by a recurrence of T-cell lymphoma of the ileum.
  • Upper and lower gastrointestinal examinations did not reveal any abnormal findings, but an abdominal aortic aneurysm was diagnosed by computed tomography, and thus was determined to be the source of the pain.
  • The patient was referred to our hospital to undergo a grafting operation; however, a laparotomy performed in July 1997 revealed an unexpected small intestinal tumor, and therefore a partial ileectomy between 15 and 70cm in an oral direction from the terminal ileum was carried out instead.
  • Histopathological and genetic examinations demonstrated diffuse small malignant lymphocytic T-cell lymphomas of the ileum invading all layers.
  • Metastasis of the facial skin and local recurrence were recognized 5 months later, and chemotherapy with THP-COP and ESHAP only resulted in progressive disease.
  • An ileac fistula was found to have formed between the intestine and abdominal wall in March 1998, and the patient died in May 1998.
  • [MeSH-major] Ileal Neoplasms / complications. Intestinal Fistula / etiology. Lymphoma, T-Cell / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12107782.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 10
  •  go-up   go-down


19. Perna AG, Jones DM, Duvic M: Lymphomatoid papulosis from childhood with anaplastic large-cell lymphoma of the small bowel. Clin Lymphoma; 2004 Dec;5(3):190-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomatoid papulosis from childhood with anaplastic large-cell lymphoma of the small bowel.
  • Lymphomatoid papulosis (LyP) is a lymphoproliferative disorder that exists on a spectrum of diseases with cutaneous CD30+ anaplastic large-cell lymphoma (ALCL).
  • Multiple treatment options are available, although none are curative.
  • Lymphomatoid papulosis is associated with primary cutaneous ALCL and other lymphoproliferative malignancies, but is rarely associated with extranodal systemic ALCL.
  • A 43-year-old man developed lymphomatoid papulosis lesions at 3 years of age, which persisted into adulthood, and he later developed ALCL of the duodenum.
  • Treatment with standard CHOP (cyclophosphamide/doxorubicin/vincristine/prednisolone) chemotherapy resulted in complete remission of his gastrointestinal lymphoma and temporary improvement of his skin lesions.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diphtheria Toxin / therapeutic use. Interleukin-2 / therapeutic use. Intestinal Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphomatoid Papulosis / pathology. Recombinant Fusion Proteins / therapeutic use
  • [MeSH-minor] Adult. Child. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Male. Prednisone / administration & dosage. Treatment Outcome. Vincristine / administration & dosage


20. Giri K, Sudar C, Arya M, Haber G, Chandra P: Diagnosis of marginal cell lymphoma of small intestine by double balloon enteroscopy. South Med J; 2008 May;101(5):561-4
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of marginal cell lymphoma of small intestine by double balloon enteroscopy.
  • A 65-year-old woman with a medical history of diabetes mellitus type 2, hypertension, an old cerebrovascular accident, and seizure disorder presented to the emergency room with lower abdominal pain of 4 weeks duration.
  • Upon physical examination, her abdomen was soft and bowel sounds were present, but there was diffuse tenderness in her lower abdomen with some guarding.
  • A computed tomography scan of her abdomen with oral and intravenous contrast showed significantly thickened small bowel loops with subjacent lymphadenopathy.
  • The biopsy showed marginal cell lymphoma.
  • The patient is presently undergoing chemotherapy.
  • Double balloon enteroscopy is a new elegant endoscopical technique that seems promising, as the endoscopist can reach undiscovered small bowel segments.
  • For the first time, it provides the means to endoscopically investigate and treat disorders of the small intestine that have previously been inaccessible to conventional endoscopy.
  • [MeSH-major] Endoscopy, Gastrointestinal / methods. Jejunal Neoplasms / diagnosis. Lymphoma / diagnosis
  • [MeSH-minor] Abdominal Pain / etiology. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Capsule Endoscopes. Female. Humans. Immunohistochemistry. Lymph Nodes / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414178.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Quintas-Cardama A, Fraga M, Antunez J, Forteza J: Primary extramedullary myeloid tumor of the breast: a case report and review of the literature. Ann Hematol; 2003 Jul;82(7):431-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary extramedullary myeloid tumor of the breast: a case report and review of the literature.
  • Primary extramedullary myeloid tumors (PEMMT) are extramedullary proliferations of myeloid cells occurring in the absence of an antecedent myeloproliferative disorder.
  • They have predilection for the skin, lymph nodes, central nervous system, and small intestine.
  • In addition, we present a new case of PEMMT of the breast who presented with a mass in her right breast mimicking a breast malignancy and was initially misdiagnosed as non-Hodgkin's lymphoma.
  • Treatment with systemic chemotherapy and local radiotherapy rendered a complete remission.
  • Most of the cases were misdiagnosed initially as lymphomas, breast carcinomas, or malignant melanomas.
  • PEMMT of the breast is a poorly recognized entity whose diagnosis frequently challenges both the pathologist and the oncologist.
  • Given the small number of patients reported no optimal treatment has been defined, but systemic chemotherapy similar to that given for acute myeloid leukemia with or without local radiotherapy may result in long remissions and avoid the progression to overt acute myeloid leukemia.
  • [MeSH-minor] Adult. Combined Modality Therapy. Diagnosis, Differential. Diagnostic Errors. Female. Humans. Neoplasm Invasiveness. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12768322.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 21
  •  go-up   go-down


22. Huang GT, Zhu GH: [Experience of the diagnosis and treatment of primary small intestine lymphoma]. Zhonghua Wai Ke Za Zhi; 2010 Jan 1;48(1):45-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experience of the diagnosis and treatment of primary small intestine lymphoma].
  • OBJECTIVE: To report the experiences of the diagnosis and treatment of primary lymphoma of the small intestine (PSIL).
  • Data of gender, age, clinical manifestation, laboratory examination, imageology examination, diagnosis and treatment of the patients was reviewed.
  • RESULTS: The most common clinical manifestations were as follow: abdominal pain, abdominal lump, bowel obstruction, gastrointestinal hemorrhage and athrepsy.
  • All the patients were diagnosed as non-Hodgkin lymphoma (NHL) by postoperative pathology (8 patients as diffuse large B-cell lymphoma, 5 as mucosa associated lymphoid tissue type B cell lymphoma and 2 as enteropathy-type intestinal T cell lymphoma).
  • Ten patients received adjuvant chemotherapy with the regimen of CHOP (cyclophosphamide + epirubicin + vincristine + prednisone) after the operation.
  • Fourteen cases were followed-up for a mean time of 30 months (range, 6 - 52 months).
  • Operation combined with chemotherapy is important for PSIL.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / therapy. Intestine, Small / pathology. Lymphoma / diagnosis. Lymphoma / therapy

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20302754.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


23. Kelleher FC, McDermott R: The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene. Eur J Cancer; 2010 Sep;46(13):2357-68
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.
  • The anaplastic lymphoma kinase gene (ALK) is a gene on chromosome 2p23 that has expression restricted to the brain, testis and small intestine but is not expressed in normal lymphoid tissue.
  • It has similarity to the insulin receptor subfamily of kinases and is emerging as having increased pathologic and potential therapeutic importance in malignant disease.
  • This gene was originally established as being implicated in the pathogenesis of rare diseases including inflammatory myofibroblastic tumour (IMT) and ALK-positive anaplastic large cell lymphoma, which is a subtype of non-Hodgkin's lymphoma.
  • In 2007, an inversion of chromosome 2 involving ALK and a fusion partner gene in a subset of non-small cell lung cancer was discovered.
  • This has been described in ALK-positive anaplastic large cell lymphoma in which ALK is fused to NPM (nucleolar protein gene) and in non-small cell lung cancer where ALK is fused to EML4 (Echinoderm microtubule-associated protein 4).
  • Therapeutic targeting of ALK fusion genes using tyrosine kinase inhibition, vaccination using an ALK specific antigen and treatment using viral vectors for RNAi are emerging potential therapeutic possibilities.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / therapy. Drug Synergism. Gene Amplification. Humans. Lung Neoplasms / genetics. Lung Neoplasms / therapy. Lymphoma, Large-Cell, Anaplastic / genetics. Lymphoma, Large-Cell, Anaplastic / therapy. Mutation / genetics. Neuroblastoma / genetics. Neuroblastoma / therapy. Pyrimidines / therapeutic use. Pyrroles / therapeutic use. Receptor Protein-Tyrosine Kinases. Receptor, IGF Type 1 / antagonists & inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20451371.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / GSK 1838705A; 0 / Pyrimidines; 0 / Pyrroles; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, IGF Type 1; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


24. Yoneda K, Takahashi H, Abe Y, Inamori M, Kato S, Uchiyama T, Iida H, Mawatari H, Hosono K, Endo H, Nozaki Y, Akiyama T, Fujita K, Yoneda M, Kobayashi N, Kirikoshi H, Kubota K, Saito S, Nakajima A: A mucosa-associated lymphoid tissue (MALT) lymphoma of the small intestine that was difficult to diagnose endoscopically. Endoscopy; 2010;42 Suppl 2:E175
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A mucosa-associated lymphoid tissue (MALT) lymphoma of the small intestine that was difficult to diagnose endoscopically.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestine, Small / pathology. Lymphoma, B-Cell, Marginal Zone / diagnosis
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Colonoscopy. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Doxorubicin / therapeutic use. Helicobacter Infections / diagnosis. Helicobacter Infections / drug therapy. Helicobacter pylori. Humans. Male. Prednisolone / therapeutic use. Rituximab. Tomography, X-Ray Computed. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20560120.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down






Advertisement